Oral News and Research

RSS

Bayer receives priority review designation from FDA for regorafenib NDA

Bayer HealthCare and Onyx Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has granted priority review designation to Bayer HealthCare's New Drug Application (NDA) filed end of April 2012 for the oral multi-kinase inhibitor regorafenib, for the treatment of patients with metastatic colorectal cancer (mCRC) whose disease has progressed after approved standard therapies.

29 Jun 2012

Results from Access’ MuGard Phase 4 trial on oral mucositis

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company developing treatments in areas of oncology and oncology supportive care, announced that Dr. Ron R. Allison of Carolina Radiation Medicine, Greenville, NC, presented results from its ongoing MuGard Phase 4 clinical trial in oral mucositis (OM) at the Multinational Association of Supportive Care in Cancer (MASCC) Conference in New York City.

29 Jun 2012

Oral health may be linked to HPV status of head and neck cancer

The chronic oral inflammatory disease periodontitis may be associated with human papillomavirus status in individuals with head and neck squamous cell carcinoma, report researchers.

28 Jun 2012

Data from Infinity’s IPI-145 pre-clinical study on inflammatory diseases

Infinity Pharmaceuticals, Inc. today reported preclinical data for IPI-145, the company's oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma. The data demonstrate potent PI3K-delta and -gamma inhibition in biochemical, cellular and whole blood assays and activity in multiple preclinical models of inflammatory disease, including rheumatoid arthritis and asthma.

28 Jun 2012

New compound could treat certain types of genetic disorders in muscles

Scientists at UCLA have identified a new compound that could treat certain types of genetic disorders in muscles. It is a big first step in what they hope will lead to human clinical trials for Duchenne muscular dystrophy.

28 Jun 2012

‘Risky’ view of thrombolysis in subtherapeutic warfarin patients disputed

A study in JAMA challenges the view that intravenous thrombolysis is a particularly risky procedure in stroke patients with subtherapeutic international normalized ratios.

27 Jun 2012

$Chinese herbal preparation reduces fragility fractures$

Chinese herbal preparation reduces fragility fractures

Herbal Fufang – a multi-herbal preparation used in traditional Chinese medicine –increases bone mineral density and reduces fragility fractures in postmenopausal women, Chinese researchers report.

27 Jun 2012

‘Risky’ view of thrombolysis in subtherapeutic warfarin patients disputed

A study in JAMA challenges the view that intravenous thrombolysis is a particularly risky procedure in stroke patients with subtherapeutic international normalized ratios.

27 Jun 2012

Preventable ER dental care in Florida cost $88M in 2010

In Florida, preventable ER visits for dental care cost that state $88 million, a new report said. In the meantime, California lawmakers sent the governor a bill for his approval that would give low-income children a new way to get dental care.

27 Jun 2012

Women with PCOS and sleep apnea more likely to develop prediabetes

Women with polycystic ovary syndrome (PCOS) who also have obstructive sleep apnea have at least three times the risk of having prediabetes compared with women who do not have PCOS, according to a new study.

27 Jun 2012

Astellas submits enzalutamide MAA with EMA for treatment of CRPC

Today, Astellas Pharma Inc. announces the submission of a European marketing authorisation application to the European Medicines Agency (EMA) for enzalutamide for the treatment of men with metastatic castration-resistant prostate cancer who have been previously treated with docetaxel-based chemotherapy.

27 Jun 2012

Talyst launches new AutoPack for oral solid medications

Talyst, a leader in pharmacy automation, announces its newest AutoPack, which automates packaging for oral solid medications.

27 Jun 2012

Toothpaste is enough for baby’s teeth

Using chlorhexidine gel on infants’ teeth achieves no more than using fluoride toothpaste alone to prevent early childhood caries, show the results of a randomized, controlled clinical trial.

26 Jun 2012

What happens after the court decides?

Heartbreak at the White House? More debate? The contingency plans? News reports include speculation about the policy and political impact of the high court's decision. Also, examinations have already begun regarding what could have been done differently.

26 Jun 2012

Experimental medication increases muscle strength in cancer patients with low testosterone levels

An experimental medication safely increases muscle strength and physical functioning among cancer patients with low testosterone levels, a new drug study finds. The results will be presented Sunday at The Endocrine Society's 94th Annual Meeting in Houston.

26 Jun 2012

Vitamin D therapy may improve symptoms of depression in women

Women with moderate to severe depression had substantial improvement in their symptoms of depression after they received treatment for their vitamin D deficiency, a new study finds. The case report series will be presented Saturday at The Endocrine Society's 94th Annual Meeting in Houston.

26 Jun 2012

Type 2 diabetes often reverses after modified weight loss surgery

Type 2 diabetes often reverses after modified weight loss surgery, especially when the duration of diabetes is less than 10 years, a new study finds. The results will be presented Tuesday at The Endocrine Society's 94th Annual Meeting in Houston.

26 Jun 2012

Exercise and diet together reduce chances of developing metabolic syndrome in obese older adults

Obese older adults can reduce their chance of developing the metabolic syndrome by losing weight through dieting alone, but adding exercise to a weight loss program has even more benefit, a new study finds. The results, to be presented Saturday at The Endocrine Society's 94th Annual Meeting in Houston, show that a combination of diet-induced weight loss and frequent exercise almost doubled the improvement in insulin sensitivity compared with dieting alone.

25 Jun 2012

First Edition: June 25, 2012

Today's headlines are focused on analysis and speculation surrounding the Supreme Court's health law ruling, which could come as early as today.

25 Jun 2012

Positive results from Lexicon’s LX4211 Phase 2b trial on type 2 diabetes

Lexicon Pharmaceuticals, Inc., announced today that LX4211, an investigational, oral, dual inhibitor of sodium glucose transporters 1 and 2 (SGLT1 and SGLT2), showed substantial, dose-dependent, statistically-significant reductions in hemoglobin A1c (HbA1c) in a Phase 2b trial in patients diagnosed with poorly-controlled type 2 diabetes who were concurrently treated with metformin, an established diabetes therapy.

25 Jun 2012